Abstract
Purpose :
To evaluate the safety and outcomes for children with paediatric uveitis who are pre-treated with intravitreal Ozurdex prior to undergoing cataract surgery.
Methods :
A retrospective analysis of the electronic medical records was perfromed to identify all patients under 16 with uveitis that had undergone Ozurdex injection prior to cataract surgery. Data items in the audit dataset included: Demographics (hospital number, DOB, Date of surgery, age at time of surgery, gender), Time between Ozurdex injection and surgery, IOP data(pre-existing OHT requiring topical IOP lowering treatment, IOP pre-injection, IOP pre-op, IOP at first post-op visit, IOP at 3 months post-op), Visual Acuity date ( VA pre-op and VA 3 months post-op).
Results :
6 eyes of 5 patients were identified between 2012 - 2021, with an average age at time of surgery of 11.3 years (SD 3.9 years).
4 out of the 6 patients had improved visual acuity at 3 months post-op. The other two patients had improved vision by 6 months. There were no cases of permanent vision loss and no patients reuired lesn explantation.
2 patients had ocular hypertension after injection or surgery, with only 1 requiring surgical trabeculectomy.
Conclusions :
This small case series shows that Ozurdex can be used safely in paediatric patients prior to cataract surgery with appropriate monitoring of patients pre and post intervention
This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.